[go: up one dir, main page]

ES2174293T3 - Microesferas farmaceuticas de acido valproico para la administracion oral. - Google Patents

Microesferas farmaceuticas de acido valproico para la administracion oral.

Info

Publication number
ES2174293T3
ES2174293T3 ES97943943T ES97943943T ES2174293T3 ES 2174293 T3 ES2174293 T3 ES 2174293T3 ES 97943943 T ES97943943 T ES 97943943T ES 97943943 T ES97943943 T ES 97943943T ES 2174293 T3 ES2174293 T3 ES 2174293T3
Authority
ES
Spain
Prior art keywords
valproic acid
hydrogen
oral administration
pharmaceutical microspheres
microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97943943T
Other languages
English (en)
Inventor
Christian Langlois
Jean-Yves Lanne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2174293T3 publication Critical patent/ES2174293T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A MICROESFERAS FARMACEUTICAS QUE CONTIENEN, COMO PRINCIPIO ACTIVO, UNA MEZCLA DE ACIDO VALPROICO Y UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN ASOCIACION CON UN SOPORTE MATRICIAL ELEGIDO ENTRE ESTERES DE GLICEROLES, ACEITES HIDROGENADOS, POLIETILENOGLICOLES ESTERIFICADOS, CERAS Y SUS MEZCLAS.
ES97943943T 1996-10-07 1997-10-03 Microesferas farmaceuticas de acido valproico para la administracion oral. Expired - Lifetime ES2174293T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9612201A FR2754177B1 (fr) 1996-10-07 1996-10-07 Microspheres pharmaceutiques d'acide valproique pour administration orale

Publications (1)

Publication Number Publication Date
ES2174293T3 true ES2174293T3 (es) 2002-11-01

Family

ID=9496427

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97943943T Expired - Lifetime ES2174293T3 (es) 1996-10-07 1997-10-03 Microesferas farmaceuticas de acido valproico para la administracion oral.

Country Status (39)

Country Link
US (3) US20020001598A1 (es)
EP (1) EP0956010B1 (es)
JP (1) JP3523270B2 (es)
KR (1) KR100334687B1 (es)
CN (1) CN100367945C (es)
AR (1) AR013613A1 (es)
AT (1) ATE216228T1 (es)
AU (1) AU731235B2 (es)
BR (1) BR9712268A (es)
CA (1) CA2267096C (es)
CO (1) CO4900080A1 (es)
CZ (1) CZ288876B6 (es)
DE (1) DE69712100T2 (es)
DK (1) DK0956010T3 (es)
DZ (1) DZ2316A1 (es)
EE (1) EE03744B1 (es)
EG (1) EG24070A (es)
ES (1) ES2174293T3 (es)
FR (1) FR2754177B1 (es)
HR (1) HRP970537B1 (es)
HU (1) HU225103B1 (es)
ID (1) ID24596A (es)
IL (1) IL128745A (es)
IS (1) IS1985B (es)
ME (1) ME00664B (es)
MY (1) MY120521A (es)
NO (1) NO325723B1 (es)
NZ (1) NZ334399A (es)
PL (1) PL190105B1 (es)
PT (1) PT956010E (es)
RS (1) RS49602B (es)
RU (1) RU2177315C2 (es)
SI (1) SI0956010T1 (es)
SK (1) SK282113B6 (es)
TR (1) TR199900789T2 (es)
TW (1) TW508251B (es)
UY (1) UY24738A1 (es)
WO (1) WO1998015268A1 (es)
ZA (1) ZA978954B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4980527B2 (ja) * 1999-06-07 2012-07-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性化合物を含有する新規の製剤および投与形
US20060223888A1 (en) * 2002-12-16 2006-10-05 Abbott Frank S Valproic acid analogues and pharmaceutical composition thereof
TWI547431B (zh) * 2004-06-09 2016-09-01 史密斯克萊美占公司 生產藥物之裝置及方法
AU2005282468B2 (en) * 2004-09-07 2011-04-21 Orphan Medical, Inc. Improved GHB compositions
US9149433B2 (en) * 2004-11-30 2015-10-06 Basf Corporation Method for formation of micro-prilled polymers
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
CN101543631B (zh) * 2008-03-28 2012-01-11 沈阳兴齐制药有限公司 含蜂蜡的微球基质、含有它的药物组合物及其用途
CN102421428B (zh) * 2009-05-12 2014-01-29 株式会社爱茉莉太平洋 用于防止脱发或促进毛发生长的组合物
WO2015071366A1 (en) * 2013-11-13 2015-05-21 Tillotts Pharma Ag Multi-particulate drug delivery system
CN104013596A (zh) * 2014-05-16 2014-09-03 安士制药（中山）有限公司 一种丙戊酸软胶囊及其制备方法
CN105456217A (zh) * 2014-08-27 2016-04-06 捷思英达医药技术（上海）有限公司 一种双丙戊酸钠缓释剂组合物及其制备方法
US20200203768A1 (en) 2017-08-24 2020-06-25 Mitsui Chemicals, Inc. Lithium secondary battery and nonaqueous electrolyte solution
JPWO2019039346A1 (ja) 2017-08-24 2020-03-26 三井化学株式会社 電池用非水電解液及びリチウム二次電池
FR3087445B1 (fr) * 2018-10-19 2021-12-17 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition lipidique pour l'encapsulation d'une substance active et permettant le controle de la vitesse de liberation de ladite substance active
CN111012753A (zh) * 2020-01-07 2020-04-17 仁和堂药业有限公司 一种提高丙戊酸钠片剂稳定性的方法
CN112274499A (zh) * 2020-11-16 2021-01-29 仁和堂药业有限公司 一种提高丙戊酸钠片剂稳定性的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2293974A1 (fr) * 1973-03-02 1976-07-09 Kaltenbach Roger Procede et dispositif pour la granulation reguliere de divers produits
US5212326A (en) * 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5185159A (en) * 1983-07-20 1993-02-09 Sanofi Pharmaceutical composition based on valproic acid and a process for preparing it
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
TW209174B (es) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
AU2016992A (en) * 1991-05-20 1992-12-30 Marion Laboratories, Inc. Multi-layered controlled release formulation
FR2682677A1 (fr) * 1991-10-17 1993-04-23 Sanofi Elf Complexe forme de l'acide propyl-2 pentene-2 ouique (e) et de son sel de sodium, sa preparation et compositions pharmaceutiques le contenant.
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5690959A (en) * 1993-05-29 1997-11-25 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Also Published As

Publication number Publication date
US8535721B2 (en) 2013-09-17
CZ288876B6 (cs) 2001-09-12
AR013613A1 (es) 2001-01-10
ME00664B (me) 2007-06-04
EP0956010B1 (fr) 2002-04-17
HK1021939A1 (zh) 2000-07-21
HUP9903855A2 (hu) 2000-05-28
BR9712268A (pt) 1999-08-31
ID24596A (id) 2000-07-27
HRP970537A2 (en) 1998-08-31
AU731235B2 (en) 2001-03-29
NO991613D0 (no) 1999-04-06
US20030157177A1 (en) 2003-08-21
DK0956010T3 (da) 2002-08-12
UY24738A1 (es) 2001-05-31
IL128745A (en) 2004-05-12
NO325723B1 (no) 2008-07-07
YU17899A (sh) 2000-03-21
SI0956010T1 (en) 2002-10-31
SK36499A3 (en) 2000-12-11
CO4900080A1 (es) 2000-03-27
FR2754177A1 (fr) 1998-04-10
EE03744B1 (et) 2002-06-17
DE69712100D1 (de) 2002-05-23
EP0956010A1 (fr) 1999-11-17
TR199900789T2 (xx) 1999-07-21
DE69712100T2 (de) 2002-11-28
CA2267096C (fr) 2003-09-16
SK282113B6 (sk) 2001-11-06
JP3523270B2 (ja) 2004-04-26
US20060263437A1 (en) 2006-11-23
ZA978954B (en) 1999-04-07
CA2267096A1 (fr) 1998-04-16
TW508251B (en) 2002-11-01
EG24070A (en) 2008-05-11
DZ2316A1 (fr) 2002-12-28
CZ121199A3 (cs) 1999-08-11
MY120521A (en) 2005-11-30
US20020001598A1 (en) 2002-01-03
PL332249A1 (en) 1999-08-30
ATE216228T1 (de) 2002-05-15
HUP9903855A3 (en) 2000-06-28
IS1985B (is) 2005-02-15
NO991613L (no) 1999-04-06
KR20000048828A (ko) 2000-07-25
RS49602B (sr) 2007-06-04
HRP970537B1 (en) 2002-08-31
JP2000504038A (ja) 2000-04-04
HU225103B1 (en) 2006-06-28
NZ334399A (en) 2000-05-26
CN100367945C (zh) 2008-02-13
FR2754177B1 (fr) 1999-08-06
PT956010E (pt) 2002-08-30
RU2177315C2 (ru) 2001-12-27
IS4996A (is) 1999-03-11
AU4560297A (en) 1998-05-05
PL190105B1 (pl) 2005-10-31
WO1998015268A1 (fr) 1998-04-16
EE9900140A (et) 1999-12-15
IL128745A0 (en) 2000-01-31
CN1232391A (zh) 1999-10-20
KR100334687B1 (ko) 2002-04-27

Similar Documents

Publication Publication Date Title
ES2174293T3 (es) Microesferas farmaceuticas de acido valproico para la administracion oral.
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
ES2183555T3 (es) Formulaciones efervescentes.
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
AR018828A1 (es) Formulaciones efervescentes solidas de rapida desintegracion para administracion oral.
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
ES2107235T3 (es) Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.
ES2033259T3 (es) Bases de liberacion controlada de productos farmaceuticos.
ES2178479T3 (es) Concentrado de principio activo con formoterol, apto para el almacenamiento.
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
AR032293A1 (es) Estuche farmaceutico
AR013117A1 (es) Una composicion farmaceutica solida en forma de comprimido que comprende un derivado de benzofurano con actividad antiarritmica adaptada para administracion oral
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
PT1185253E (pt) Forma de administracao oral para administracao de uma combinacao fixa de tramadol e diclofenac
TR199902175T2 (xx) Parasetamol i�eren yutma tableti.
ES2253378T3 (es) Extractos de espermatofitos con actividad antineoplasica.
ES2179533T3 (es) Formulacion de medicamento con liberacion controlada del principio activo.
ES2166988T3 (es) Terapia de administracion uniforme de farmacos.
ES2164310T3 (es) Comprimidos matriciales para uso oral y de liberacion prolongada que contienen la sal sodica de la tianeptina.
UY26371A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
ES2156220T3 (es) Preparacion transdermica que contiene un metabolito de loratidina con accion antihistaminica.
AR023699A1 (es) Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
AR025351A1 (es) Agonistas retinoides selectivos par

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 956010

Country of ref document: ES